| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases | ||
Phase 2 Readout example | Phase 2 | — | Subscribe to access the data. | Gene Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Rocket Pharmaceuticals, Inc.$3.91
-0.34 (-8.11%)
D 34Pipeline Score Overvalued Biotech · Clinical
Market Cap
323.21 M
EPS
-1.88
P/E Ratio
-
Value Trade
8.33 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
31.45 M
Operating CF
-45.39 M
Total Assets
285.41 M
Total Liabilities
47.37 M
Equity
238.04 M
D/E Ratio
12,345
-12.17 %
Week
-19.35 %
1 Month
-19.78 %
3 Month
4.59 %
6 Month
-93.17 %
5 Year
-87.87 %
All Time
Cash Data
Cash Position
144.38 M
Monthly Burn
15.13 M
Runway
7.6 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.95 M
52 Week Range
2.19 - 5.45
% held by Insiders
5.12 %
% held by Institutions
90.03 %
Enterprise Value
203.60 M
Total Shares
109.12 M
Short %
21.61 %
Float Shares
84.02 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rocket Pharmaceuticals, Inc.
303Total events
5Upcoming
95Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 5
TBD
T2PRV Granted
Rocket eligible for Rare Pediatric Disease Priority Review Voucher if KRESLADI approved
TBD
T1Confirmatory Trial Result
Confirmation of clinical benefit based on longer-term follow-up data and post-marketing registry
TBD
T2Product Launch
Company looks forward to making KRESLADI available to eligible patients in the U.S.
Event history 298
Jun 12, 2026
▲PRV SoldDesignation
Closing of sale of Rare Pediatric Disease Priority Review Voucher for $180 million
Jun 9, 2026
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
Jun 4, 2026
May 7, 2026
▲FDA ApprovalKRESLADIApprovedFDA Decision
KRESLADI granted FDA accelerated approval
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
May 7, 2026
▲PRV SoldDesignation
Rare Pediatric Disease Priority Review Voucher monetized for $180 million
Apr 28, 2026
Q2 2026
▲First Patient DosedRP-A701Trial
Dosing of first patient in Phase 1 study of RP-A701 for BAG3-DCM anticipated in mid-2026
BAG3-related dilated cardiomyopathysource ↗
Q2 2026
◆Trial InitiationRP-A701Trial
First patient dosing in Phase 1 study of RP-A701 anticipated in mid-2026
BAG3-related dilated cardiomyopathysource ↗
Mar 28, 2026
◆PDUFA DateKRESLADIApprovedRegulatory Filing
PDUFA date for KRESLADI for severe LAD-I
severe LAD-Isource ↗
Mar 27, 2026
▲FDA ApprovalKRESLADIApprovedFDA Decision
FDA approval of KRESLADI for pediatric patients with severe LAD-I
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
Mar 27, 2026
▲PRV GrantedKRESLADIApprovedDesignation
FDA granted Rare Pediatric Disease Priority Review Voucher
severe leukocyte adhesion deficiency-I (LAD-I)source ↗
Drug Pipeline Intelligence
D34
Pipeline Score $112M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.4x
rNPV / MCap Top 45%
Micro Cap (rank 502 of 911)
Percentile RankRocket Pharmaceuticals, Inc. faces pipeline headwinds (34/100), with $663M risk-adjusted pipeline value, led by Tislelizumab in Locally Advanced Rectal Carcinoma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tislelizumab Small molecule | Locally Advanced Rectal Carcinoma | Phase 2 | NCT06312982 | 19% | $387M | RECRUITING | 375 | - | - | Dec 1, 2026 | - | May 21, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
KRESLADI | severe LAD-I | Phase 1/2 | 2024-08-05 | In the global Phase 1/2 study of KRESLADI for severe LAD-I, a 100% survival rate was demonstrated over a 4-year follow-up period, indicating the drug's potential efficacy in treating this severe pediatric genetic disorder. Read More | Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Enrollment of patients ongoing in the pivotal Phase 2 study of RP-A501 for the treatment of Danon disease and the Phase Read More | |
KRESLADI | severe LAD-I | Phase 1/2 | 2024-08-05 | In the global Phase 1/2 study of KRESLADI for severe LAD-I, a 100% survival rate was demonstrated over a 4-year follow-up period, indicating the drug's potential efficacy in treating this severe pediatric genetic disorder. Read More | Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Enrollment of patients ongoing in the pivotal Phase 2 study of RP-A501 for the treatment of Danon disease and the Phase Read More | |
KRESLADI | severe LAD-I | Phase 1/2 | 2024-08-05 | In the global Phase 1/2 study of KRESLADI for severe LAD-I, a 100% survival rate was demonstrated over a 4-year follow-up period, indicating the drug's potential efficacy in treating this severe pediatric genetic disorder. Read More | Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Enrollment of patients ongoing in the pivotal Phase 2 study of RP-A501 for the treatment of Danon disease and the Phase Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RCKT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RCKT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RCKTRocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
Rocket Pharmaceuticals has successfully closed the sale of a Rare Pediatric Disease Priority Review Voucher for $180 million. This sale is expected to provide substantial funding for the company's initiatives focused on pediatric diseases. The transaction highlights the value of such vouchers in accelerating drug development for rare conditions.
Read more →RCKTRocket Pharmaceuticals to Participate in Upcoming June 2026 Investor Conferences
Rocket Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. CEO Gaurav Shah will engage in a fireside chat and management will hold investor meetings at both events. Webcasts of the presentations will be available on the company's website.
Read more →RCKTRocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals has released its financial results for the first quarter of 2026, highlighting recent progress in its operations. The report provides insights into the company's financial performance and developments during this period. Further details regarding specific advancements or challenges were not disclosed in the article.
Read more →RCKTRocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
Rocket Pharmaceuticals has announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. This transaction is expected to significantly strengthen the company's financial position, allowing for further investment in its pipeline of genetic therapies aimed at rare disorders. The PRV was awarded by the U.S. Food and Drug Administration.
Read more →RCKT▼ -19.6%on this news
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals has received FDA approval for KRESLADI™, the first gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I). This approval is based on clinical data showing increased neutrophil surface expression. The company also received a Rare Pediatric Disease Priority Review Voucher, which it plans to monetize. KRESLADI aims to address a critical need in treating this ultra-rare genetic disorder.
Read more →RCKT▲ +10.6%on this news
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline. The pivotal Phase 2 trial for RP-A501 in Danon disease is set to resume in the first half of 2026, while the PDUFA date for KRESLADI™ is scheduled for March 28, 2026. The company also anticipates dosing the first patient in a Phase 1 study for RP-A701 in mid-2026, supported by a strong cash position.
Read more →RCKT▲ +5.6%on this news· ran to +20% by day 3
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals announced its participation in two upcoming investor conferences, the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. CEO Gaurav Shah will engage in a fireside chat and management will hold investor meetings at both events. The conferences are scheduled for March 2 and March 10, 2026, respectively.
Read more →RCKTRocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rocket Pharmaceuticals will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with CEO Gaurav Shah presenting on January 14. The company focuses on genetic therapies for rare disorders and has several late-stage clinical programs. A webcast of the presentation will be available on their website.
Read more →RCKTRocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI for severe LAD-I on track for
Rocket Pharmaceuticals, Inc. has reported its financial results for the third quarter of 2025 and highlighted key operational updates. The company confirmed the resumption of its Phase 2 pivotal study for RP-A501 targeting Danon disease, scheduled to continue in the first half of 2026. Additionally, KRESLADI is set to be evaluated by the FDA with a PDUFA date of March 28, 2026. Rocket's leadership team has seen new appointments, and its solid financial reserves extend operational capacity into the second quarter of 2027.
Read more →RCKT▲ +23.1%on this news
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Prescription Drug User Fee Act (PDUFA) target action date is
Rocket Pharmaceuticals announced that the FDA has accepted the resubmission of the Biologics License Application (BLA) for KRESLADI, a gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I). The PDUFA target action date is set for March 28, 2026. Clinical trials showed that KRESLADI was well tolerated, meeting all primary and secondary endpoints with a 100% survival rate among patients 12 months post-infusion. If approved, Rocket will also be eligible for a Rare Pediatric Disease Priority Review Voucher.
Read more →RCKT▲ +28.9%on this news
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease CRANBURY, NJ
Rocket Pharmaceuticals announced that the FDA has lifted the clinical hold on its pivotal Phase 2 trial for RP-A501, aimed at treating Danon disease. The hold was removed in under three months, validating the company's efforts to address FDA concerns promptly. The trial will now resume with a recalibrated dosage strategy and modified immunomodulatory regimen. With six patients already treated, Rocket anticipates further updates as more patients receive the therapy.
Read more →RCKTRocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress Prioritizing development of RP-A501 (Danon disease), RP-A601 (PKP2-ACM), and RP-A701 (BAG3-DCM) to advance AAV cardiovas
Rocket Pharmaceuticals reported its financial results for Q2 2025, highlighting key advancements in its gene therapy pipeline. The company is focusing on RP-A501 for Danon disease, RP-A601 for PKP2-ACM, and RP-A701 for BAG3-DCM, with regulatory designations aiding their progress. Improvements include a significant cash reserve for operational needs extending into 2027. However, a restructuring plan is set to reduce the workforce by about 30%, signaling an adjustment in strategic priorities and resource allocation.
Read more →RCKTRocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs Restructuring pipeline to focus on AAV cardiovascular platform (Danon disease, PKP2-ACM, BAG3-DCM
Rocket Pharmaceuticals has announced a strategic corporate reorganization aimed at prioritizing its cardiovascular programs centered on its AAV platform. The restructuring will involve a workforce reduction of around 30% and is intended to decrease operating expenses by approximately 25%, extending the company's cash runway to mid-2027. Programs targeting Danon disease, PKP2-ACM, and BAG3-DCM will be emphasized, while anticipated delays are noted for Fanconi Anemia and Pyruvate Kinase Deficiency programs. This shift reflects Rocket's focus on high-opportunity areas within its pipeline.
Read more →RCKT▲ +16.8%on this news
Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy CRANBURY, NJ
Rocket Pharmaceuticals received FDA Regenerative Medicine Advanced Therapy designation for its gene therapy RP-A601, aimed at treating PKP2-arrhythmogenic cardiomyopathy. This designation is based on positive Phase 1 clinical trial data showcasing encouraging safety and efficacy outcomes. RP-A601 represents a significant advancement in addressing a serious heart disease with high unmet medical need. With RMAT designation, Rocket can expect intensive FDA guidance and expedited review processes, further supporting its development efforts.
Read more →RCKT▼ -62.8%on this news
Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Conference call to be held later today at 8:30 a.m.
Rocket Pharmaceuticals announced an update on the Phase 2 clinical trial of RP-A501 for Danon disease, reporting a serious adverse event that led to the death of a trial participant. The FDA has placed a clinical hold on the trial as Rocket conducts a root cause analysis of the incident. The company remains in dialogue with the FDA and is focused on patient safety while aiming to resume the trial as quickly as possible. Despite these challenges, Rocket continues to prioritize its efforts in developing gene therapies for rare diseases.
Read more →RCKT▲ +11.1%on this news
NVESTOR DE I CK INVESTOR DECK INVESTOR DECK Preliminary Data from Phase 1 Trial of RP-A601 May 2025 2025 Rocket Pharmaceuticals, Ltd. All rights reserved FORWARD LOOKING STATEMENT AND DISCLOSURES Various statements in th
Rocket Pharmaceuticals has released preliminary data from a Phase 1 trial of RP-A601, a gene therapy for arrhythmogenic cardiomyopathy caused by PKP2 mutations. The early safety assessments indicate a favorable profile for the therapy, which is aimed at treating a rare genetic condition. However, the final efficacy and long-term outcomes of RP-A601 remain to be validated in future studies. The company also highlights the need for caution in interpreting forward-looking statements regarding the therapy's future prospects.
Read more →RCKT▲ +5.1%on this news
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress Phase 2 pivotal study of RP-A501 for Danon disease is ongoing; Program update expected mid-year 2025 Initial data from th
Rocket Pharmaceuticals has reported its financial results for the first quarter of 2025, showcasing a strong cash position of approximately $318.2 million, allowing operational stability into late 2026. The ongoing Phase 2 study of RP-A501 for Danon disease is highlighted, with an update expected mid-year 2025, alongside initial data from the Phase 1 study of RP-A601 for PKP2-ACM anticipated in May 2025. Additionally, the company plans to submit an IND for its BAG3-DCM program later this year. However, the company also noted an increase in operating expenses and continued net losses.
Read more →RCKTRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress Dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease; Program update expected in the f
Rocket Pharmaceuticals reported its financial results for Q4 and full year 2024, highlighting the ongoing dosing in the Phase 2 study of RP-A501 for Danon disease. The company also noted a New England Journal of Medicine publication detailing the Phase 1 study of RP-A501, which presented long-term safety and efficacy data. They reported a significant cash position to sustain operations through mid-2026, despite experiencing an increase in net losses compared to the previous year. Meanwhile, initial data from the Phase 1 study of RP-A601 is expected in early 2025, along with ongoing regulatory assessments for additional therapies.
Read more →RCKTRocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress Enrollment completed in September and dosing ongoing in the Phase 2 pivotal study of RP-A501 for Danon disease Updated Ph
Rocket Pharmaceuticals announced its financial results for the third quarter of 2024, highlighting several key developments in its pipeline. Notably, the company completed enrollment in the Phase 2 pivotal study of RP-A501 for Danon disease, with ongoing dosing. The initiation of a Rolling Biologics License Application (BLA) submission for RP-L102 for Fanconi Anemia was also reported. Despite a net loss of $66.7 million for the quarter, Rocket maintains a considerable cash position aimed to fund operations into 2026.
Read more →RCKTRocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress Enrollment of patients ongoing in the pivotal Phase 2 study of RP-A501 for the treatment of Danon disease and the Phase
Rocket Pharmaceuticals announced its second quarter 2024 financial results, highlighting ongoing patient enrollment in pivotal Phase 2 studies for RP-A501 and RP-A601. The company showcased long-term follow-up data for KRESLADI, demonstrating a promising 100% survival rate for patients treated for severe LAD-I. With a cash reserve of approximately $278.8 million, Rocket has a financial runway into 2026 as it prepares for FDA approval of KRESLADI. However, the company reported a significant net loss and faces inherent risks linked to third-party dependencies and forward-looking uncertainties.
Read more →RCKTRocket Pharmaceuticals Provides Regulatory Update on KRESLADI TM (marnetegragene autotemcel; marne-cel) CRANBURY, N.J.
Rocket Pharmaceuticals provided an update on its gene therapy KRESLADI (marnetegragene autotemcel) for severe leukocyte adhesion deficiency-I, following a Complete Response Letter from the FDA. The letter requests limited additional Chemistry Manufacturing and Controls (CMC) information to complete its review. Positive data from a Phase 1/2 study indicated 100% survival at 12 months for treated patients, and KRESLADI was reported to be well tolerated. Rocket expressed optimism about working closely with the FDA to expedite the review process.
Read more →RCKTRocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipate
Rocket Pharmaceuticals reported its first quarter 2024 financial results, highlighting substantial progress in its clinical programs. Notably, the EMA has accepted the marketing authorization application for RP-L102 for Fanconi Anemia, while commercial preparations for KRESLADI, targeting severe LAD-I, are underway. The company maintains a strong financial position with around $330.3 million in cash, which supports operational plans into 2026. Additionally, Rocket appointed a new Chief Financial Officer to enhance its strategic and financial oversight.
Read more →RCKTRocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership exper
Rocket Pharmaceuticals has appointed Aaron Ondrey as its new Chief Financial Officer, bringing over 20 years of experience in financial management and strategy from his previous roles, including CFO of Mirati Therapeutics. This appointment reflects Rocket's commitment to strengthening its leadership as it transitions into a commercial-stage gene therapy company. Additional updates to the corporate leadership team aim to enhance the company's capabilities across its pipeline of genetic therapies. The changes aim to position Rocket for operational excellence and support its initiatives targeting rare diseases.
Read more →RCKTRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress Advancing leading pipeline of six disclosed programs across AAV cardiovascular and LV hematology portfolio
Rocket Pharmaceuticals reported its financial results for Q4 and the full year 2023, showcasing advancements in its gene therapy pipeline across AAV cardiovascular and LV hematology. The company plans to launch KRESLADI for severe LAD-I, with a PDUFA date set for June 30, 2024, and has an operational runway until 2026 due to strong cash reserves. Despite these positive outcomes, Rocket continues to face challenges, including a significant net loss and reliance on third parties for development and marketing activities.
Read more →RCKTRocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI TM (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) New Prescription Drug User Fee Act (PDUFA) dat
Rocket Pharmaceuticals announced that the FDA has extended the review timeline for KRESLADITM (marnetegragene autotemcel) for the treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) to June 30, 2024. This extension allows the FDA additional time to review clarifying Chemistry, Manufacturing, and Controls (CMC) information. The drug has shown promising results, including a 100% survival rate at 12 months in a Phase 1/2 study, with no serious adverse events reported. The company remains focused on collaborating closely with the FDA to bring this therapy to patients as soon as possible.
Read more →RCKT▼ -5.1%on this news
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Prescripti
Rocket Pharmaceuticals announced that the FDA has accepted the Biologics License Application for RP-L201, a gene therapy aimed at treating Severe Leukocyte Adhesion Deficiency-I (LAD-I). The therapy has received several designations, including Regenerative Medicine Advanced Therapy and Fast Track. The FDA's target action date for their review is March 31, 2024. Positive results from Phase 1/2 trials indicate a 100% survival rate at 12 months post-infusion for patients treated. These promising findings illustrate the potential of RP-L201 as a crucial alternative to bone marrow transplants, the current treatment option for LAD-I.
Read more →RCKTS E E K I N G G E N E T H E R A P Y C U R E S Rocket Pharmaceuticals Danon Disease Program Update
Rocket Pharmaceuticals has updated its program for treating Danon Disease, a severe genetic cardiac condition. Phase 1 clinical data indicates positive outcomes, with patients showing sustained improvements in key health metrics. Recent authorizations, such as the approval of an ICD 10 Code for Danon Disease, further underscore the program's significance. The company's commitment to advancing its gene therapy efforts is clear, as it aims to initiate pivotal trials soon.
Read more →RCKTRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results Advanced pipeline of four clinical programs across AAV cardiology and LV hematology portfolios delivering strong results
Rocket Pharmaceuticals reported strong financial and operational results for Q4 and the full year of 2022, highlighting advancements in their AAV cardiology and LV hematology programs. The company is advancing four clinical gene therapy programs and has established in-house manufacturing capabilities, boosting their position in the AAV cardiac gene therapy space. Notably, the FDA granted RMAT designation for RP-A501, enhancing its prospects for Danon Disease treatment. Despite a substantial net loss for the year, Rocket maintains a strong financial outlook with $400 million projected to sustain their operations through 2024.
Read more →RCKTRocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease CRANBURY, N.J.
Rocket Pharmaceuticals has received RMAT designation from the FDA for its RP-A501 gene therapy targeting Danon Disease, which currently has no approved therapies. This designation highlights the therapy's potential benefits based on data from early clinical trials. The company plans to begin a pivotal Phase 2 trial in the second quarter of 2023, taking advantage of expedited regulatory guidance. The positive implications of this designation could lead to more rapid access to treatment for patients suffering from this rare genetic condition.
Read more →RCKTINVESTOR DECK INVESTOR DECK INVESTOR DECK 41st Annual J.P. Morgan Healthcare Conference Company Presentation Gaurav Shah, MD Chief Executive Officer
Rocket Pharmaceuticals provided an overview of its operations and future expectations during the 41st Annual J.P. Morgan Healthcare Conference. The company aims to develop innovative gene therapies for serious conditions, emphasizing its focus on safety and efficacy in clinical trials. Rocket is financially robust, with sufficient cash reserves to support its pipeline through 2024. Upcoming milestones include regulatory filings for several gene therapy candidates in the near future.
Read more →RCKT▼ -13.9%on this news
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting Based on ongoing FDA discussion, Rocket to pursue a biomarker-based composite endp
Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting Based on ongoing FDA discussion, Rocket to pursue a biomarker-based composite endpoint for a single arm, open-label pivotal trial with a na
Read more →RCKTRocket Pharmaceuticals Completes Acquisition of Renovacor Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy CRA
Rocket Pharmaceuticals Completes Acquisition of Renovacor Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated CRANBURY, N.J. - December 1, 2022 - Rocket Pharmaceuticals, Inc. (NASDAQ: RC
Read more →RCKTRocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress - Positive updates from Phase 1 clinical trial in Danon Disease showed RP-A501 was well tolerated with evidence of durabl
Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress - Positive updates from Phase 1 clinical trial in Danon Disease showed RP-A501 was well tolerated with evidence of durable treatment effect and disease improvement for both pediat
Read more →RCKT▲ +13.7%on this news
Update from Phase 1 Trial of RP-A501 Gene Therapy Treatment for Danon Disease
Update from Phase 1 Trial of RP-A501 Gene Therapy Treatment for Danon DiseaseSeptember 30, 2022 DISCLAIMER Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidanc
Read more →RCKTExecution Version VOTING AGREEMENT THIS VOTING AGREEMENT (this " Agreement ") is made and entered into as of September __, 2022, by and between Renovacor, Inc., a Delaware corporation (the " Company ") and the undersigne
THIS VOTING AGREEMENT (this "Agreement") is made and entered into as of September __, 2022, by and between Renovacor, Inc., a Delaware corporation (the "Company") and the undersigned stockholder (the "Stockholder") of Rocket Pharmaceuticals, Inc., a Delaware corporation ("Parent
Read more →RCKTRocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress - Reported positive safety data at ASGCT from pediatric cohort of Phase 1 Danon Disease study that demonstrated RP-A501
Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress - Reported positive safety data at ASGCT from pediatric cohort of Phase 1 Danon Disease study that demonstrated RP-A501 was well-tolerated; efficacy update across pediatric as we
Read more →RCKTRocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results - Positive Phase 1 data from Danon Disease gene therapy trial demonstrated sustained benefit across clinical, functional
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and - Cash position of $388.7M; runway expected into 2H'23 - CRANBURY, N.J. - Feb. 24, 2022 - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainabl
Read more →RCKT▲ +6.2%on this news
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress - Treatment initiated in pediatric patient cohort in Danon Disease trial of RP-A501- - Treatment completed in nine of nin
Rocket Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Progress - Treatment initiated in pediatric patient cohort in Danon Disease trial of RP-A501- - Treatment completed in nine of nine patients in LAD-1 Phase 1/2 trial; favorable safety prof
Read more →RCKTRocket Pharmaceuticals Announces $26.4 Million Private Placement CRANBURY, N.J.
Rocket Pharmaceuticals Announces $26.4 Million Private Placement CRANBURY, N.J.-- Aug. 30, 2021-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today anno
Read more →RCKTRocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress - Working with FDA on Changes to Clinical Trial Protocol in Danon Disease Trial; Rocket Anticipates Trial Will Resume in
Rocket Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Progress - Working with FDA on Changes to Clinical Trial Protocol in Danon Disease Trial; Rocket Anticipates Trial Will Resume in 3Q- Durable Benefit Observed in Low Dose Cohort (6.7e13 d
Read more →RCKTRocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress -RP-A501 Phase 1 Trial for the Treatment of Danon Disease Placed on Clinical Hold To Address FDA Request For Additional R
Rocket Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Progress -RP-A501 Phase 1 Trial for the Treatment of Danon Disease Placed on Clinical Hold To Address FDA Request For Additional Risk Mitigation Methods in Protocol; No New Safety Events O
Read more →RCKTRocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021
Rocket Pharmaceuticals Announces Private Exchange Transaction Regarding Its Outstanding Convertible Senior Notes due 2021 NEW YORK - June 8, 2020 - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline
Read more →RCKTRocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021
Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021 NEW YORK - February 11, 2020 - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipelin
Read more →RCKTRocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector - REGENXBIO grants Rocket exclusive, worldwide rights to NAV AAV9 for the development and comme
Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector - REGENXBIO grants Rocket exclusive, worldwide rights to NAV AAV9 for the development and commercialization of treatments for Danon - Investigational New
Read more →RCKTAmerican Society of Gene & Cell Therapy
American Society of Gene & Cell TherapyMay 18, 2018 Gaurav Shah, M.D.Chief Executive Officer and President Important Information Cautionary Statement Regarding Forward-Looking Statements Various statements in this release concerning Rocket's future expectations, plans and prospe
Read more →RCKTRocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights Enters 2018 as a Public Company with Solid Financial Position Following Successful Completion of Merger with Inotek Pharmaceutica
Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights Enters 2018 as a Public Company with Solid Financial Position Following Successful Completion of Merger with Inotek Pharmaceuticals and Subsequent Follow-on Offering Multiple Milestones
Read more →RCKTRocket Pharmaceuticals and Inotek Pharmaceuticals Complete Merger Transaction - Strong Support by Shareholders Approving Merger Proposal- - Multi-Platform Approach to Develop Gene Therapies for Rare Diseases- - Multiple
Rocket Pharmaceuticals and Inotek Pharmaceuticals Complete Merger Transaction - Strong Support by Shareholders Approving Merger Proposal- - Multi-Platform Approach to Develop Gene Therapies for Rare Diseases- - Multiple Programs in the Clinic in 2018; Data from One or More Pro
Read more →RCKTInotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket Pharmaceuticals - First Clinical Program in Fanconi Anemia Demonstrating Early H
Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage Gene Therapy Company, Rocket - First Clinical Program in Fanconi Anemia Demonstrating Early Hematological Stabilization in Patients - - Additional First-in-human Resul
Read more →RCKTInotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases - Company to Leverage Lentiviral and AAV Gene Therapy Platforms to Targ
Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare - Company to Leverage Lentiviral and AAV Gene Therapy Platforms to Target Rare Genetic Diseases - - Transaction to Advance Rocket s Growi
Read more →RCKTInotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights
Inotek Pharmaceuticals Corporation Reports Second Quarter 2017 Financial Results and Operational Highlights LEXINGTON, Mass August 3, 2017 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and co
Read more →RCKTInotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update - Trabodenoson FDC Demonstrated Moderate IOP Reduction Over Latanoprost Alone When D
Inotek Pharmaceuticals Announces Top-line Results of Phase 2 Fixed-dose Combination Trial of Trabodenoson and Provides Corporate Update - Trabodenoson FDC Demonstrated Moderate IOP Reduction Over Latanoprost Alone When Dosed in the Morning, But Had Comparable Efficacy Dosed in
Read more →RCKTInotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights
Inotek Pharmaceuticals Corporation Reports First Quarter 2017 Financial Results and Operational Highlights Mass May 10, 2017 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization
Read more →RCKTInotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost Scheduled to Meet with FDA on Monotherapy Program
Inotek Completes Patient Recruitment in Phase 2 Trial of a Fixed-dose Combination (FDC) of Trabodenoson and Latanoprost Scheduled to Meet with FDA on Monotherapy Program LEXINGTON, Mass April 11, 2017 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharm
Read more →RCKTInotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights
Inotek Pharmaceuticals Corporation Reports Fiscal Year 2016 Financial Results and Operational Highlights LEXINGTON, Mass. March 16, 2017 Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commer
Read more →RCKTInotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma - Trial Did Not Achieve Superiority to Placebo at All 12 Time Points- - Diurnal IOP Reduction of 4.25mmHg at Three Months wi
Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma Achieve Superiority to Placebo at All 12 Time Points- - Diurnal IOP Reduction of 4.25mmHg at Three Months with Trabodenoson 6% Once-a-day Dose, Statistically Superior to Placebo - S
Read more →RCKTNovember 2016 Corporate Presentation Forward Looking Statements This presentation contains forward-looking statements that are based on our management s belief and assumptions and on information currently available to ou
November 2016 Corporate Presentation Forward Looking Statements contains forward-looking statements that are based on our management s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these f
Read more →RCKTInotek Pharmaceuticals Corporation Reports Third Quarter 2016 Financial Results and Operational Highlights
Inotek Pharmaceuticals Corporation Reports Third Quarter 2016 Financial Results and Operational LEXINGTON, Mass November 9, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company or Inotek ), a clinical-stage biopharmaceutical company focused on the discovery, deve
Read more →RCKTInotek Pharmaceuticals Appoints Timothy Barberich to Board of Directors Lexington, MA
Inotek Pharmaceuticals Appoints Timothy Barberich to Board of Directors Lexington, MA September 29, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company or Inotek ), a clinical stage biopharmaceutical company focused on the discovery, development and commercializ
Read more →RCKTInotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma - Top-line Data Expected in December 2016
Inotek Pharmaceuticals Announces the Completion of the Recruitment Phase of MATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma - Top-line Data Expected in December 2016 - LEXINGTON, Mass August 24, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a c
Read more →RCKTInotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors Lexington, MA
Inotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors Lexington, MA August 18, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company or Inotek ), a clinical stage biopharmaceutical company focused on the discovery, development and commercializ
Read more →RCKTInotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results and Operational Highlights -Initiated Phase 2 Study of Fixed-Dose Combination of Trabodenoson and Latanoprost - -Phase 3 MATrX-1 Trial of T
Inotek Pharmaceuticals Corporation Reports Second Quarter 2016 Financial Results and Operational Highlights -Initiated Phase 2 Study of Fixed-Dose Combination of Trabodenoson and Latanoprost- -Phase 3 MATrX-1 Trial of Trabodenoson in Glaucoma on Track for Completion in 4Q 2016
Read more →RCKTInotek Pharmaceuticals Announces Proposed Public Offering of $50 Million of Convertible Senior Notes due 2021 LEXINGTON, MASS
Inotek Pharmaceuticals Announces Proposed Public Offering of $50 Million of Convertible Senior Notes due 2021 LEXINGTON, MASS August 1, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company ) has commenced an underwritten public offering of $50 million aggregate
Read more →RCKTInotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent - Covers Combination of Trabodenoson and a Prostaglandin for Reducing Intraocular Pressure in Glaucoma
Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent - Covers Combination of Trabodenoson and a Prostaglandin for Reducing Intraocular Pressure in Glaucoma - LEXINGTON, Mass July 22, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a cli
Read more →RCKTInotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson , a Novel Treatment for Glaucoma, and Latanoprost -Data Expected in 2017
Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost -Data Expected in 2017- LEXINGTON, Mass July 12, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage bi
Read more →RCKTInotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational Highlights
Inotek Pharmaceuticals Corporation Reports First Quarter 2016 Financial Results and Operational LEXINGTON, Mass May 11, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization
Read more →RCKTInotek Pharmaceuticals Announces Changes to Board of Directors Pharmaceutical Industry Leader J. Martin Carroll Elected Chairperson as of 2016 Annual Meeting; Argeris Karabelas, Ph.D. and Isai Peimer to transition off th
Inotek Pharmaceuticals Announces Changes to Board of Directors Pharmaceutical Industry Leader J. Martin Carroll Elected Chairperson as of 2016 Annual Meeting; Argeris Karabelas, Ph.D. and Isai Peimer to transition off the Board LEXINGTON, MA, April 4, 2016 - Inotek Pharmaceuti
Read more →RCKTInotek Pharmaceuticals Corporation Reports Fiscal Year 2015 Financial Results and Operational Highlights
Inotek Pharmaceuticals Corporation Reports Fiscal Year 2015 Financial Results and Operational Highlights LEXINGTON, Mass March 23, 2016 Inotek Pharmaceuticals Corporation (the Company or Inotek ), (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discove
Read more →RCKTInotek Pharmaceuticals Strengthens Patent Estate for Lead Product Candidate Trabodenoson
Inotek Pharmaceuticals Strengthens Patent Estate for Lead Product Candidate Trabodenoson LEXINGTON, Mass March 9, 2016 Inotek Pharmaceuticals Corporation (the Company or Inotek ) (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development an
Read more →RCKTInotek Pharmaceuticals Appoints Carsten Boess to Board of Directors LEXINGTON, Mass. (BUSINESS WIRE)
Inotek Pharmaceuticals Appoints Carsten Boess to Board of Directors LEXINGTON, Mass. (BUSINESS WIRE) January 12, 2016 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of the
Read more →RCKTInotek Pharmaceuticals Corporation Reports Third Quarter 2015 Financial Results and Operational Highlights -Initiated MATrX-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson , a Novel Treatment for Glaucoma- -C
Inotek Pharmaceuticals Corporation Reports Third Quarter 2015 Financial Results and Operational Highlights -Initiated MATrX-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma- -Completed $79.2 Million Public Offering - -Expanded Manag
Read more →RCKTInotek Pharmaceuticals Initiates Dosing of MAT Rx -1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma -Top-line data expected in the fourth quarter of 2016- Lexington, MA
Inotek Pharmaceuticals Initiates Dosing of MATRx-1, the First Pivotal Phase 3 Clinical Trial of Trabodenoson, a Novel Treatment for Glaucoma -Top-line data expected in the fourth quarter of 2016- Lexington, MA October 16, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK)
Read more →RCKTInotek Pharmaceuticals Appoints Gary M. Phillips, MD, MBA, to Board of Directors -Pharmaceutical Industry Veteran with Ophthalmology Leadership Experience- Lexington, MA
Inotek Pharmaceuticals Appoints Gary M. Phillips, MD, MBA, to Board of Directors -Pharmaceutical Industry Veteran with Ophthalmology Leadership Experience- Lexington, MA October 13, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company or Inotek ), a clinical sta
Read more →RCKTInotek Pharmaceuticals Corporation Announces Closing of $79.2 Million Public Offering Including Exercise in Full of Underwriters Option to Purchase Additional Shares Lexington, MA
Inotek Pharmaceuticals Corporation Announces Closing of $79.2 Million Public Offering Including Exercise in Full of Underwriters Option to Purchase Additional Shares MA August 18, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company or Inotek ), a clinical stage
Read more →RCKTInotek Pharmaceuticals Corporation Announces Pricing of $68.9 Million Public Offering Lexington, MA
Inotek Pharmaceuticals Corporation Announces Pricing of $68.9 Million Public Offering Lexington, MA August 12, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company or Inotek ), a clinical stage biopharmaceutical company focused on the discovery, development and c
Read more →RCKTInotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results and Operational Highlights End-of-Phase 2 Meeting with FDA Informs Phase 3 Development Plan for Trabodenoson Key Hires Strengthen Senior Ma
Inotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results and Operational Highlights End-of-Phase 2 Meeting with FDA Informs Phase 3 Development Plan for Trabodenoson Key Hires Strengthen Senior Management Team 1st Phase 3 Study to Commence in 4Q15 wit
Read more →RCKTInotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Trabodenoson, a Novel Treatment for Glaucoma Pivotal Studies Designed to Show Superiority to Placebo 1 st Pha
Inotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Trabodenoson, a Novel Treatment for Glaucoma Pivotal Studies Designed to Show Superiority to Placebo 1st Phase 3 Study to Commence in 4Q15 with Top-line Data In 2016
Read more →RCKTInotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors -Global Drug Development Executive with Leadership in Ophthalmology
Inotek Pharmaceuticals Appoints Richard N. Spivey PharmD, Ph.D. to Board of Directors -Global Drug Development Executive with Leadership in Ophthalmology- LEXINGTON, Mass July 21, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical compan
Read more →RCKTChris Erdman 781.235.3060 chris@macbiocom.com Company Contact: David P. Southwell, CEO 781-676-2116 dpsouthwell@inotekpharma.com Inotek Pharmaceuticals Corporation Reports First Quarter 2015 Operational an
David P. Southwell, CEO dpsouthwell@inotekpharma.com Inotek Pharmaceuticals Corporation Reports First Quarter 2015 Operational and Financial Results LEXINGTON, MA May 15, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused
Read more →RCKTChris Erdman 781.235.3060 chris@macbiocom.com Company Contact: David P. Southwell, CEO 781-676-2116 dpsouthwell@inotekpharma.com Inotek Pharmaceuticals Corporation Reports 2014 Financial Results
David P. Southwell, CEO dpsouthwell@inotekpharma.com Inotek Pharmaceuticals Corporation Reports 2014 Financial Results LEXINGTON, Mass April 1, 2015 Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the Company ), a clinical-stage biopharmaceutical company focused on the dis
Read more →Competitive Position
How RCKT ranks across every disease it competes inCompetitive Position is a premium feature
See how RCKT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial